Breaking news on liver disease, hepatitis
Liver Disease - Can-Fite Successfully Completed Phase I Clinical Trial With Its 2nd Drug CF102 published
Wed, 07 May 2008 02:00:00 PDT
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced the successful completion of a phase I clinical trial with its second pipeline drug, CF102. Can-Fite is developing CF102 for the treatment of liver disease including hepatocellular carcinoma (HCC) and hepatitis C (HCV). The trial was a first exposure in humans and was conducted in the US under an IND in 25 healthy volunteers who were given the drug at 1 of 5 escalating doses.
Health Department Encourages Public To Learn Risk Factors For Viral Hepatitis published
Mon, 05 May 2008 00:00:00 PDT
The Alabama Department of Public Health and the Centers for Disease Control and Prevention urge the public to learn the risk factors of viral hepatitis during May, Hepatitis Awareness Month. Viral hepatitis is caused by several different viruses, and it can be a serious liver disease. Dr. Donald Williamson, state health officer, said, "More than three million Americans have been infected with hepatitis C, a blood-borne virus which often does not cause symptoms.
New Findings: The Anti-Fibrotic Mechanism Of Plant Extract Cpd 861 published
Sat, 03 May 2008 09:00:00 PDT
In human hepatic stellate cells, the key cells involved in both the synthesis and degradation of matrix proteins (mainly collagens) in the liver, the plant extract Cpd 861 can regulate the expression levels of collagen synthesis and degradation-related genes, thus demonstrating an antifibrotic effect.This research, performed by Dr. Xue-Hai Tan and his colleagues at the Beijing Genomics Institute, was published in the World Journal of Gastroenterology.
P-HOP Event To Provide Free Hepatitis C Testing To The Community - P-HOP Recognizes May As Hepatitis Awareness Month published
Fri, 02 May 2008 02:00:00 PDT
Philadelphia Hepatitis Outreach Project (P-HOP), in partnership with the New Pathways for Women Project, is conducting a community health fair on May 31, 2008 from 10 a.m. to 3 p.m. at the New Pathways for Women Project office at 2539 Germantown Avenue, Philadelphia.
Anti-HAV Antibodies In Beta-Thalassemia published
Thu, 01 May 2008 05:00:00 PDT
Thalassemic patients were found to present a higher prevalence of anti-HAV IgG antibodies than matched healthy subjects from the same geographic area. This finding is difficult to explain, but it may be attributed to the higher vulnerability of thalassemics to HAV infection and to passive transfer of anti-HAV antibodies by blood transfusion.
Managing Chinese Obese Children With Non-Alcoholic Fatty Liver Disease published
Thu, 01 May 2008 05:00:00 PDT
Short-term lifestyle intervention is more effective than short-term vitamin E capsule therapy on NAFLD and so it should be the first step in the management of children with NAFLD.This study, performed by a team led by Professor Li Liang, is described in a research article to be published on March 14, 2008, in the World Journal of Gastroenterology.NAFLD is likely to reach epidemic proportions in children worldwide in this decade.
Anti-HBe May Play A Role In The Progression Of The Disease Of Hepatitis B published
Thu, 01 May 2008 03:00:00 PDT
Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.This study, performed by a team led by Dr.
High Circulating D-Dimers Are Associated With Presence Of Ascites published
Thu, 01 May 2008 03:00:00 PDT
The liver is the production site of most of the proteins which favour and inhibit the process of coagulation and fibrinolysis. Patients with liver cirrhosis may develop serious coagulopathy and a hyperfibrinolytic state, which contributes to the bleeding tendency. Plasma levels of fragment D-dimer (D-dimer) represent an accurate marker of fibrinolytic activity. The finding of a high plasma D-dimer concentration in patients with liver cirrhosis, decompensated with ascites, led Agarwal et al.
Clinical Update - Debio 025 In Hepatitis C published
Tue, 29 Apr 2008 00:00:00 PDT
Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy results of a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent in-vitro and in-vivo anti-hepatitis C (HCV) effect.
European Commission Approves Viread For Chronic Hepatitis B published
Mon, 28 Apr 2008 03:00:00 PDT
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the European Commission has granted marketing authorisation for VireadŽ (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in all 27 member states of the European Union. A once-daily tablet, Viread works by blocking hepatitis B virus (HBV) DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells.
Interim Results From Boceprevir Phase II Study In Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL published
Sun, 27 Apr 2008 00:00:00 PDT
Schering-Plough Corporation (NYSE: SGP) reported that results from a planned interim analysis of an ongoing Phase II study of boceprevir, its investigational oral hepatitis C protease inhibitor, in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). The ongoing study evaluates boceprevir in 28-week and 48-week treatment regimens.
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared To Adefovir At 96 Weeks In Hepatitis B Positive Patients published
Sun, 27 Apr 2008 00:00:00 PDT
Bristol-Myers Squibb Company (NYSE: BMY) announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week results (primary endpoint).
Three Studies Presented At 43rd EASL Showed Higher SVR For PEGASYS(R) (Peginterferon Alfa-2a) Plus Ribavirin Than Peginterferon Alfa-2b Plus Ribavirin published
Sun, 27 Apr 2008 00:00:00 PDT
Roche announced that new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) (peginterferon alfa-2a) plus ribavirin had a greater chance of achieving a sustained virological response (SVR) than patients on peginterferon alfa-2b.
Final Results Of Ideal Study Presented At Annual Meeting Of The European Association For The Study Of The Liver (EASL) published
Sun, 27 Apr 2008 00:00:00 PDT
Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease.
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Response In Phase IIa Study published
Sun, 27 Apr 2008 00:00:00 PDT
Roche's investigational therapy for chronic hepatitis C virus (HCV) infection, R1626, has shown a significant end-of-treatment response rate when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin). R1626 also shows a high barrier to the development of resistance.
Important Progress Toward Control Of Hepatitis B And C published
Sat, 26 Apr 2008 00:00:00 PDT
Scientists presenting at today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) reported encouraging findings regarding the potential efficacy of treatment strategies using new drugs designed to combat hepatitis B and C.
Biolex Therapeutics Researchers Present Locteron(R) Phase 2a Hepatitis C Trial Results At EASL Conference published
Fri, 25 Apr 2008 14:00:00 PDT
Biolex Therapeutics, Inc. announced that the results from its SELECT-1 Phase 2a clinical trial of LocteronŽ will be presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL). As a controlled-release interferon alfa, Locteron is designed to improve patient care through a more favorable side-effect profile compared to existing pegylated interferon products and AlbuferonŽ, each of which lacks a controlled-release mechanism.
Gilead Announces 72-Week Data From Two Pivotal Phase III StudiesEvaluating Viread(R) For The Treatment Of Chronic Hepatitis B published
Fri, 25 Apr 2008 13:00:00 PDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of detailed 72-week data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily VireadŽ (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
Data On Investigational Compounds Being Co-Developed By Tibotec For The Treatment Of Chronic Hepatitis C Presented At EASL 2008 published
Fri, 25 Apr 2008 03:00:00 PDT
Tibotec BVBA, a global pharmaceutical company dedicated to the discovery and development of innovative drugs that fight infectious diseases, is now building a portfolio of novel antiviral therapies to treat hepatitis C virus (HCV). The investigational protease inhibitors (PI), telaprevir (VX-950) and TMC435350, are being co-developed by Tibotec with Vertex and Medivir, respectively.
Positive Findings In Treating Patients With Advanced Hepatitis C published
Fri, 25 Apr 2008 02:00:00 PDT
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) For The Treatment Of Chronic Hepatitis B published
Fri, 25 Apr 2008 01:00:00 PDT
Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of detailed 72-week data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily VireadŽ (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb Data Presentation At European Association For The Study Of Liver (EASL) Annual Meeting published
Fri, 25 Apr 2008 01:00:00 PDT
Valeant Pharmaceuticals (NYSE:VRX) announced that results from the treatment week 12 analysis for its Phase IIb clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, have been accepted for presentation as a late breaker at the European Association for the Study of Liver (EASL) 43rd Annual Meeting in Milan, Italy, April 23-27, 2008.
Pharmasset Adds Two Cohorts To R7128 Hepatitis C Study published
Fri, 25 Apr 2008 00:00:00 PDT
Pharmasset, Inc. (Nasdaq: VRUS) will enroll two additional cohorts in the on- going Phase 1 study protocol to evaluate 4 weeks of combination therapy with R7128. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of hepatitis c virus (HCV) that is being developed through Pharmasset's collaboration with Roche. Cohort 3 will study R7128 1000mg BID in treatment-naive patients with HCV genotype 1.
NAFLD AND NASH Linked To Metabolic Syndrome And Cardiovascular Disease published
Fri, 25 Apr 2008 00:00:00 PDT
Data presented at today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) further confirm that nonalcoholic fatty liver disease (NAFLD) and its most severe form, nonalcoholic steatohepatitis (NASH), are associated with the metabolic syndrome and pose an increased risk of cardiovascular disease.
Antipodean Pharmaceuticals Announces Results Of Phase 2 Study Of Lead Compound MitoQ(R) published
Fri, 25 Apr 2008 00:00:00 PDT
Antipodean Pharmaceuticals, Inc. announced, at the European Meeting for the Study of the Liver (EASL), the positive results of a Phase 2 trial of its lead compound MitoQ(R) (mitoquinone) in liver disease. The trial, conducted by Dr. Edward Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, successfully met the primary clinical endpoint, the reduction of elevated liver enzymes.
)
|
|
